Nanobiotix S.A. American Depositary Shares
Compare this stock
NBTX Stock Report Card
$
47%
Performance
Score:
51/100
NBTX returned -7.36% in the last 12 months. Based on the other stocks in its sector with an average return of -7.41%, its performance is above average giving it a grade of 50 of 100.
Sentiment
Score:
63/100
NBTX had a bullish sentiment score of 63.40% across Twitter and StockTwits over the last 12 months. It had an average of 30.90 posts, 5.83 comments, and 30.90 likes per day.
Volatility
Score:
20/100
NBTX has had a lower than average amount of volatility over the last 12 months giving it a grade of 20 of 100.
Nanobiotix S.A. American Depositary Shares Summary
Nasdaq / NBTX
Healthcare
Biotechnology
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
NBTX scored poorly on our reportcard. Here are some similar companies and how they performed.
